ClinicalTrials.gg
RecruitingNCT06532474Updated Jul 9, 2026

Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies

An observational study in Spinal Muscular Atrophy, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged 5 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by St. Jude Children's Research Hospital · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
24
Ages
5 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 121 studies in Muscular Atrophy, Spinal with a site in United States — 21 open to participants now, 39 under way, 7 of them phase 3. Muscular Atrophy, Spinal · United States.

Planned enrollment
36th of 43
24 · median 75
Started
2025
with 7 others
Observational
43 of 121
11 open now
Primary completion
2027-09
later than 13 of 38 live
Registered
103rd of 121
by date

Among the 121 studies in Muscular Atrophy, Spinal with a site in United States, this one is the 36th largest by planned enrollment of the 43 observational ones that give a count, is one of 8 that started in 2025, is one of 43 observational ones, reaches primary completion later than 13 of the 38 other live ones, and was the 103rd registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

21 of the 121 studies in Muscular Atrophy, Spinal with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.

This study: 5 Years to 20 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies in Muscular Atrophy, Spinal with a site in United States, or all of them as a file.
02

Study summary

In this observational study, researchers are looking at the effects of spinal muscular atrophy (SMA) drugs on the muscles and nerve cells in patients with SMA.

Primary Objectives

  • To evaluate the feasibility and reliability of performing MR functional imaging in exercising muscle in patients with SMA.
  • To evaluate patients with SMA types 2 and 3 at baseline and longitudinally at 6 and 12 months

Secondary Objectives

  • To describe the MR functional bioenergetics response in muscles in five potential groups of patients with spinal muscular atrophy: untreated, actively treated with nusinersen (Spinraza®) or onasemnogene abeparvovec (Zolgensma®), actively treated with risdiplam (Evrysdi®), switching from Spinraza or Zolgensma to Evrysdi and initiating combination therapy of Spinraza or Zolgensma with Evrysdi .
  • To identify changes in motor function in patients with SMA types 2 and 3 who initiate treatment with risdiplam.
  • To obtain biomarkers in blood, urine, and muscle tissue to provide proof-of-concept support for risdiplam effect on skeletal muscle.
  • To obtain quality of life and disability data from participants in this study.
Read the detailed description

This is an observational study to demonstrate the feasibility of performing MR functional imaging in exercising muscle in patients with SMA. The participants will be prescribed medication by their treating physician, they will not receive any drug as part of this study.

Participants participating in the ML43225 study, will be put into groups depending on their type of SMA and the drugs they may or may not be taking. They will be asked to come to clinic 3 times over one year. Each visit will include magnetic resonance (MR) studies, a muscle ultrasound, a nerve test, muscle function testing, lung function testing, blood work, vital signs, and participants will be asked about their quality of life and daily life activities. After participants have completed the 3 required visits, they will be taken off study.

03

Conditions studied

  • Spinal Muscular Atrophy

Keywords

  • Spinal Muscular Atrophy (SMA)
  • SMA drugs
  • Responses of Skeletal Muscle
  • SMN-directed therapies
  • Eyrysdi
  • Spinraza
  • Zolgensma
04

Who can participate

Ages eligible
5 Years to 20 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Those who meet the Eligibility criteria and consent to enrollment on the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Genetic confirmation of SMA with homozygous deletion of SMN1 or compound heterozygous deletion/mutation of SMN1
  • Two, three, or four copies of SMN2
  • Age 5 to 20 years
  • Non-ambulatory participants: maximum function sitting or standing with support, HFMSE score at screening between 10 and 45 points.
  • Ambulatory participants: minimum function of independent walking, able to walk unassisted a minimum of 100 meters at screening, HFMSE score at screening between 40 and 66.
  • SMN-directed therapy inclusion:

    • Current Evrysdi prescription (Group 1)

      • Must have Evrysdi prescription through their treating physician
      • If initiating combined therapy using Evrysdi with Spinraza or Zolgensma, must have not started Evrysdi treatment OR
    • Current Spinraza or Zolgensma prescription (Group 2)

      • For patients on Spinraza, must have been taking Spinraza for at least 12 months at screening (4 loading and 2 maintenance doses) and following the FDA-recommended dosing schedule
      • For patients on Zolgensma, must have been dosed at least one year prior to screening
      • Must have Spinraza or Zolgensma prescription through their treating physician OR
    • Changing from Spinraza or Zolgensma to Evrysdi (Group 3)

      • For patients on Spinraza, must have been taking Spinraza for at least 12 months at screening (4 loading and 2 maintenance doses) and following the FDA-recommended dosing schedule
      • For patients on Zolgensma, must have been dosed at least one year prior to screening
      • Must have voluntarily decided to switch therapies based on discussion with their treating physician
      • Must have Evrysdi prescription through their treating physician but have not yet initiated treatment OR
    • Have never received any SMN-directed therapies (Group 4)

Exclusion criteria

Exclusion Criteria:

  • Any chronic medical condition, planned surgery, or treatment with a medication which would impact safety or participation of the study at the investigator's discretion
  • Inability to perform reliably the motor function testing or the exercise testing in the MR scanner.
  • Fat fraction > 35% in calf or bicep at screening MRI
  • Need for routine non-invasive ventilation support.
  • Non-oral nutritional support, e.g., gastrostomy tube feeding.
  • Any ferrous metal implants (e.g., spinal rods) that preclude testing in a MR scanner.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
24 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort 1

    Current Evrysdi prescription or initiating combination therapy with Evrysdi to current Spinraza or Zolgenzma prescription

  • Cohort 2

    Current Spinraza or Zolgensma prescription

  • Cohort 3

    Changing from Spinraza or Zolgensma to Evrysdi

  • Cohort 4

    Have never received any SMN-directed therapies

06

What researchers measure

Primary outcomes

  1. Feasibility of performing MR functional imaging in SMA patients

    MR functional imaging is considered feasible if ≥ 80% of MRI protocol eligible patients can complete 100% of imaging assessments at baseline and 6 months.

    Time frame: At baseline and at 6 months (+/- 14 days)

  2. Reliability of performing MR functional imaging in SMA patients

    MR functional imaging is considered reliable if the test-retest reliability is ≥ 0.80 for key imaging biomarkers.

    Time frame: At baseline and at 6 months (+/- 14 days)

  3. Compare skeletal muscle oxidative phosphorylation bioenergetics in patients with SMA types 2 and 3 (phosphocreatine)

    Real-time 31P MR spectroscopy and CrCEST MRI will be used to measure phosphocreatine within the muscles at rest, during an exercise protocol, and during post-exercise recovery to baseline. Both measure the recovery time in seconds.

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  4. Compare skeletal muscle oxidative phosphorylation bioenergetics in patients with SMA types 2 and 3 (creatine concentrations)

    Real-time 31P MR spectroscopy and CrCEST MRI will be used to measure creatine concentrations within the muscles at rest, during an exercise protocol, and during post-exercise recovery to baseline. Both measure the recovery time in seconds.

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  5. Measure intramuscular fat fraction in major muscle extremity in patients with SMA types 2 and 3

    Measurement of thickness of muscle compared to fat on MRI, measured in percentage.

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  6. Measure electrophysiological tests of motor neuron function to repetitive nerve stimulation in patients with SMA types 2 and 3

    Electrophysiological testing: Compound motor action potential (CMAP, measured in millivolts), motor unit number estimate (MUNE, average 200-400 for most limb muscles), and repetitive stimulation at 3 Hz - right ulnar to abductor digiti minimus and right fibular/peroneal nerve to tibialis anterior muscle. A decrease of more than 40% in the amplitude of CMAP is considered abnormal.

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

Secondary outcomes

  1. Identify changes in motor function in non-ambulant patients and ambulant patients with SMA types 2 and 3

    The Hammersmith Functional Motor Scale Expanded (HFMSE) has a score range from 0-66 with lower scores indicating poorer overall motor function.

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  2. Identify changes in motor function in non-ambulant patients with SMA types 2 and 3 - Revised Upper Limb Module

    The Revised Upper Limb Module (RULM) has a score range 0-37 with lower scores indicating poorer upper limb motor function.

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  3. Identify changes in motor function in non-ambulant patients with SMA types 2 and 3 - Block and Box Test

    The Block and Box Test (BBT) is a measure of gross manual dexterity and is scored by counting the number of blocks carried from one compartment to another. Higher scores are indicative of better manual dexterity.

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  4. Identify changes in motor function in ambulant patients with SMA types 2 and 3 - 6-Minute Walk

    The 6-Minute Walk (6MW) Test measures how far someone can walk in six minutes, a higher score indicates better exercise tolerance score. A low score correlates with lower function.

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  5. Identify changes in motor function in ambulant patients with SMA types 2 and 3 - 10 Meter Walk/Run

    The 10 Meter Walk/Run (10MW) Test is measured in seconds and assesses walking speed over a short distance. Longer times indicate lower motor function

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  6. Identify changes in motor function in ambulant patients with SMA types 2 and 3 - 4-Stair Climb

    The 4-Stair Climb (4SC) Test is measured in seconds and assesses lower extremity power and motor function. Longer times indicate lower motor function

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  7. Identify changes in motor function in ambulant patients with SMA types 2 and 3 - Supine-to-Stand Test

    The Supine-to-Stand (STS) Test is measured in seconds and assesses the ability to move from laying on your back to standing up straight. Longer times indicate lower motor function.

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  8. Identify changes in motor function in ambulant patients with SMA types 2 and 3 - Timed Up-and-Go Test

    The Timed Up-and-Go (TUG) Test is measured in seconds and assesses the ability to stand up from sitting in a chair, walk 10 feet, turn around, walk back, and sit down. Longer times indicate lower motor function

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  9. Assess myometry, or measurement of muscle strength

    Myometry measures force in pounds or kilograms and measures the strength of a muscle group. The more force measured indicates more muscle strength.

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  10. Muscle ultrasound thickness and echogenicity of 5 muscles - 2 upper limb and 3 lower limb

    Muscle thickness is measured in centimeters and echogenicity is measured in gray-scale value. Muscle thickness and echogenicity are related to muscle strength, physical function, muscle mass, and quality of muscle.

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  11. Plasma neurofilament light (NF-L) and phosphorylated heavy chain (pNF-H) levels

    The NF-L and pNF-H levels are measured in nanograms per milliliter from blood samples and can be an indicator of nerve cell damage. Higher values normally mean more nerve damage is occurring.

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  12. Blood SMN protein levels

    SMN protein levels are measured in nanograms per milliliter from blood samples. Higher values indicate more SMN protein production which is normally deficit in people with SMA.

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  13. Pyruvic acid (mg/dL)

    This parameters has been added to better understand systemic glycolysis in this population in the context of measuring bioenergetics in muscle via fMRS. A normal blood pyruvic acid level is between 0.3 and 1.5 milligrams per deciliter (mg/dL). Elevated pyruvic acid in glycolysis usually indicates a disruption in the normal metabolic pathway.

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  14. Lactic Acid (millimoles per liter)

    This parameter has been added to better understand systemic glycolysis in this population in the context of measuring bioenergetics in muscle via fMRS. Normally, blood lactate levels are between 1-2 mmol/L when not exercising. Elevated lactic acid during glycolysis indicates that the body is primarily relying on anaerobic glycolysis, meaning it is breaking down glucose for energy without sufficient oxygen, leading to a buildup of lactate as a byproduct.

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  15. Lactate dehydrogenase (LDH) (units per liter (U/L)

    This parameters has been added to better understand systemic glycolysis in this population in the context of measuring bioenergetics in muscle via fMRS. Normal LDH levels in children vary by age. Normal adult range is 140-280 U/L. An elevated level of lactate dehydrogenase (LDH) in glycolysis indicates an increased rate of anaerobic metabolism.

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  16. Trough risdiplam drug levels

    Trough risdiplam drug level is measured in nanograms per milliliter from blood samples and indicates the concentration of risdiplam in someone's blood stream. Higher values mean someone has more risdiplam exposure. This will only be tested on participants who are taking the drug risdiplam.

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  17. Quality of life (QOL) and disability information - Pediatric Quality of Life Inventory (PedsQL)

    The Pediatric Quality of Life Inventory (PedsQL) is a 23-item questionnaire measuring health-related quality of life in children and adolescents aged 2-18. Higher scores indicate better quality of life.

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  18. QOL and disability information - Pediatric Outcomes Data Collection Instrument (PODCI)

    The Pediatric Outcomes Data Collection Instrument (PODCI) is an 83-86 item questionnaire that measures the health-related quality of life for children and adolescents with musculoskeletal disorders aged 2-18. Higher scores indicate better quality of life.

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

  19. QOL and disability information - SMA Health Index (SMA-HI)

    The SMA Health Index (SMA-HI) is a 107 item questionnaire that measures a patient's perception of disease burden in 15 areas of health related to SMA. Higher scores indicate more SMA disease burden

    Time frame: At baseline and longitudinally at 6 (+/- 14 days) and 12 months (+/- 14 days)

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2027, 23 months after the start.

Of 58 observational studies under Muscular Atrophy, Spinal, half reached primary completion within 88 months of starting (the median), counting those still running; a quarter within 36. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2024
First posted
Aug 1, 2024
StartActual
Oct 29, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2028
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06532474
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Oct 29, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Jul 9, 2026

Study contacts

Jean Laboe, RN
Contact
referralinfo@stjude.org
901-595-1693
Richard Finkel, MD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion